Scientists find technology used in Covid vaccine to cure HIV
In a major scientific breakthrough, researchers in Australia may have found a new way to bring the world one step closer to curing HIV.Scientists at the Peter Doherty Institute for Infection and Immunity in Melbourne have developed a method to "wake up" hidden HIV viruses inside the human body, potentially allowing them to be removed completely.The ability for the HIV virus to conceal itself inside some white blood cells has been one of the main challenges for scientists looking for a cure. This also makes it nearly impossible for the immune system or even strong medicines to detect and destroy it fully.advertisement
But now, in their quest to find the best treatment, they have found a way to get the virus out of the their hiding.This hidden form of HIV is known as a "reservoir." While today's medicines can control the virus, they cannot remove it. People with HIV still need lifelong treatment to stay healthy and prevent spreading the virus.But researchers have now used mRNA technology, the same kind used in Pfizer and Moderna's Covid-19 vaccines, to deliver special instructions to these hidden cells.These instructions make the virus come out of hiding, so it can potentially be eliminated from the body.The problem before was that the white blood cells hiding HIV didn't accept the fat bubbles, or lipid nanoparticles (LNPs), that carry the mRNA.But the Melbourne team designed a new version of these fat bubbles called LNP X, which successfully entered the tricky white blood cells and delivered the mRNA.advertisementDr. Paula Cevaal, one of the lead researchers, said the early results were so surprising that the team repeated the experiments many times to confirm what they were seeing. "We were overwhelmed by how big the difference was," she told The Guardian.The research, published in Nature Communications, is still in the early stages and was done using cells donated by HIV patients in the lab.Next steps would involve testing the method in animals, followed by human trials to check if the treatment is safe and truly effective.The team believes this could be a major moment in the fight against HIV, and possibly even helpful in treating other diseases like certain cancers.Trending Reel
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 hours ago
- Time of India
A new HIV drug promises 99.9% protection. But it's making Indian health activists wary; Why?
The US Food and Drug Administration (FDA) has approved lenacapavir, a new injectable drug that claims to offer 99.9% protection against HIV. But concerns are being raised in India over its affordability and accessibility, particularly through the public healthcare system. The injection costs around ₹24 lakh ($28,218) for two doses administered six months apart. Lenacapavir belongs to the class of HIV prevention drugs known as pre-exposure prophylaxis (PrEP). However, India's National AIDS Control Organisation (NACO) has not included PrEP in its public programmes so far. "Our govt distributes condoms to break HIV transmission, it provides antiretroviral therapy drugs to prevent parent-to-child transmission of HIV, but it hasn't ever given PrEP to youngsters who are likely to indulge in high-risk behaviour," said health activist Ganesh Acharya. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Hanoi: Unsold Furniture Liquidation 2024 (Prices May Surprise You) Unsold Furniture | Search Ads Learn More Undo He added that NACO had made it mandatory for its counselling centres to provide information on PrEP a couple of years ago. He also expressed concern that 75% of the 88% people diagnosed with HIV in Mumbai in 2023–24 were from the 15–49 age group. PrEP, however, remains available only in the private sector. Experts call for government action, tiered pricing PrEP has existed for over a decade and is widely used in developed countries. In India, public health discussions around PrEP only began recently. Live Events A doctor from a government hospital said, "They set up a committee, then a white paper was brought out that served as a backgrounder for guidelines that were drawn up last year. However, there has been no development since." Dr Ishwar Gilada of the People's Health Organisation (India) said, "The govt should distribute PrEP to check the spread of the disease, which has only been increasing in recent years. The total number of HIV-positive people in India increased from 2.2 million to 2.5 million in a few years." According to him, sexually transmitted infections have been rising in Mumbai. "A recent survey in Mumbai among men who have sex with men found that 60% of them were positive for the human papilloma virus. While gonorrhoea and chlamydia vanished 25 years ago, their numbers are shooting up," he said. He suggested a three-tier pricing structure: full price for those who can afford it, subsidised pricing for some, and free access for those unable to pay. NACO officials were not available for comment. India has also not approved HIV self-testing kits. "We have self-testing kits for pregnancy, diabetes, and Covid, but policymakers fear about the mental health of people after a positive result in self-testing HIV kits," said Dr Gilada. A senior doctor suggested that similar fears may be behind the delay in rolling out PrEP publicly, as officials worry it might encourage risky behaviour. Hope for lower-cost versions as UNAIDS urges price drop Bala from Bombay Gay called lenacapavir a "monumental milestone forward in HIV treatment and prevention," but added that the current price point makes it inaccessible in India. "So, we have to wait and see if prices will come down over time," he said. Dr Gilada expressed hope that Indian manufacturers licensed by Gilead Sciences might eventually offer the injection at less than $100 per year. "India can do it," he said. UNAIDS, in a recent statement, urged Gilead Lifesciences to reduce the price of the new drug to improve global access.
India Today
6 hours ago
- India Today
From headache to hospitalization: How seasonal flu has changed post-COVID
In the past, the seasonal flu was considered a bothersome condition that resembled the common cold or "fun flu" and was characterized by minor headaches, a mild fever, some body pains, and exhaustion. Since then, the flu's clinical manifestation and/or intensity have evolved. On the other side of COVID, more people show up in hospitals with what appear to be routine flu-like symptoms that rapidly worsen because of serious respiratory issues. Dr. Pratibha Walde, Consultant - Internal Medicine, Manipal Hospital, Kharadi, Pune explains what has changedOur bodies have changed: The body's reaction to influenza viruses, co-infections, and, of course, the long-term consequences of COVID-19 has been altered by post-pandemic immunological sensitivity. A previously healthy people may develop myocarditis (inflammation of the heart tissue), pneumonia, acute respiratory distress syndrome (ARDS), and in certain situations, multi-organ hospitalisations are on the rise: The most at risk will always be elderly people, children, and those with a history of heart problems, diabetes, or asthma. However, the number of hospitalizations for severe flu-related diseases is increasing, especially among younger people without comorbidities. What usually begins as a sore throat or moderate headache can frequently worsen into a high-grade fever, dyspnea, and chest pain, necessitating oxygen therapy or an admission to the intensive care is also requiring more complex intervetions: The rise in instances requiring the procedure or pleural tapping is one of the most alarming trends we have observed. This entails removing contaminated fluid from the pleural space that envelops the lungs. These situations usually occur when the flu causes substantial pleural effusions or an empyema, which is pus in the pleural space. Large pleural effusions and empyema can cause lung collapse, sepsis, or impairment of lung function if left untreated. The probability of needing mechanical ventilation is further impacted by bruised lungs and postponed treatment, particularly if the infection triggered acute respiratory distress syndrome. With a guarded prognosis, recovery from multi-system failures like ARDS can be Early medical attention is crucial: It is necessary to seek medical attention as soon as possible. It has been shown that antiviral drugs such as oseltamivir (Tamiflu) work best when taken during the first 48 hours of symptoms. While rest, hydration, supportive care, and symptom monitoring are important, it's imperative to get medical help if symptoms initial line of defense is still vaccination: The annual flu shot has a new significance in a world where COVID-19 has changed everything. It is for the public as well as those at risk and the elderly. Vaccination can reduce the need for invasive operations and hospital stays when combined with early detection and medical treatment. Seasonal flu is more than just "the flu" these days. The clinical course is more severe and less predictable. Early symptom detection and timely medical evaluation could make the difference between a full recovery and an extended hospital to India Today Magazine
Time of India
7 hours ago
- Time of India
This drug offers 99.9% protection against HIV, but there's a catch
The US FDA has approved lenacapavir, the first twice-yearly injection for HIV prevention, which provides near-complete protection. However, its cost — ₹24 lakh per shot — may make it inaccessible in India
